This study aims to determine the incidence of HCC in patients with HCV or NAFLD complicated by advanced fibrosis, inferred from measurements of liver stiffness, and, additionally, to identify other clinical predictors of HCC, such as alpha-fetoprotein (AFP), that may aid the decision of whether or not to screen each patient. Here, AFP is linked to metabolic dysfunction-associated steatotic liver disease.